APLASTIC ANEMIA IN CENTER TUNISIA
(Abstract release date: 05/19/16)
EHA Library. ACHOUR B. 06/09/16; 134667; PB1767
Prof. Dr. BECHIR ACHOUR
Contributions
Contributions
Abstract
Abstract: PB1767
Type: Publication Only
Background
Aplastic anaemia is a rare but very serious blood disease, combining a central pancytopenia and bone marrow hypocellularity. Its etiology remains mostly unknown. Treatment is either allogeneic hematopoietic stem cell or on immunosuppressive therapy.
Aims
1- To analyze the epidemiological, clinical and laboratory patients.2. Evaluate the terms and therapeutic results.3- To study the different responses and survival depending on the treatment administered.
Methods
This is a retrospective study conducted over 14 years (January 2000 - December 2013) which included 95 patients with acquired aplastic anemia, diagnosed and treated at the hematology department of the University Hospital Farhat Hached hospital Sousse.
Results
The median age of patients was 32 years. The sex ratio was 1.26. At diagnosis, all patients were symptomatic. An anemic syndrome associated with hemorrhagic syndrome was the main factor of discovery (44.2%). At the initial blood count, pancytopenia was observed in 92.6% of patients. The myelogram showed a poor marrow in 85.2% of patients. A bone marrow biopsy, bone marrow was wealth 0-1 95.8% of patients. Myelosuppression was, moderate in 33 patients (34.7%), severe in 26 patients (27.4%) and severe in 36 patients (37.9%) by the score of Camitta. Fourteen patients underwent a bone marrow allograft. One patient received the anti-lymphocyte serum in combination with ciclosporin. Immunosuppressive treatment with cyclosporin alone was undertaken in 51 of our patients. Forty-two patients received androgen therapy, prescribed alone or in combination with ciclosporin or corticosteroids. At the end of our study: 35 patients (36.8%) were in CR, 6 patients (6.3%) in PR, 14 patients (14.7%) and RM 39 patients (41.1%) in Failure . One patient was lost to follow just after diagnosis. The factors that significantly influenced the response were the severity of myelosuppression, sex, hemoglobin, the rate of white blood cell, the neutrophil rate and allograft. The overall survival rate at 2 years was 47.3% at 5 years and 44.9%. The allograft is the most significant prognostic factor for survival.
Conclusion
Despite progress regarding treatment protocols, changes in the Aplastic anaemia is often fatal. The overall mortality rate in our series is due to the problem of access to specific therapies, namely the allogeneic hematopoietic stem cell and lymphocyte serum.
Session topic: E-poster
Keyword(s): Bone marrow failure
Type: Publication Only
Background
Aplastic anaemia is a rare but very serious blood disease, combining a central pancytopenia and bone marrow hypocellularity. Its etiology remains mostly unknown. Treatment is either allogeneic hematopoietic stem cell or on immunosuppressive therapy.
Aims
1- To analyze the epidemiological, clinical and laboratory patients.2. Evaluate the terms and therapeutic results.3- To study the different responses and survival depending on the treatment administered.
Methods
This is a retrospective study conducted over 14 years (January 2000 - December 2013) which included 95 patients with acquired aplastic anemia, diagnosed and treated at the hematology department of the University Hospital Farhat Hached hospital Sousse.
Results
The median age of patients was 32 years. The sex ratio was 1.26. At diagnosis, all patients were symptomatic. An anemic syndrome associated with hemorrhagic syndrome was the main factor of discovery (44.2%). At the initial blood count, pancytopenia was observed in 92.6% of patients. The myelogram showed a poor marrow in 85.2% of patients. A bone marrow biopsy, bone marrow was wealth 0-1 95.8% of patients. Myelosuppression was, moderate in 33 patients (34.7%), severe in 26 patients (27.4%) and severe in 36 patients (37.9%) by the score of Camitta. Fourteen patients underwent a bone marrow allograft. One patient received the anti-lymphocyte serum in combination with ciclosporin. Immunosuppressive treatment with cyclosporin alone was undertaken in 51 of our patients. Forty-two patients received androgen therapy, prescribed alone or in combination with ciclosporin or corticosteroids. At the end of our study: 35 patients (36.8%) were in CR, 6 patients (6.3%) in PR, 14 patients (14.7%) and RM 39 patients (41.1%) in Failure . One patient was lost to follow just after diagnosis. The factors that significantly influenced the response were the severity of myelosuppression, sex, hemoglobin, the rate of white blood cell, the neutrophil rate and allograft. The overall survival rate at 2 years was 47.3% at 5 years and 44.9%. The allograft is the most significant prognostic factor for survival.
Conclusion
Despite progress regarding treatment protocols, changes in the Aplastic anaemia is often fatal. The overall mortality rate in our series is due to the problem of access to specific therapies, namely the allogeneic hematopoietic stem cell and lymphocyte serum.
Session topic: E-poster
Keyword(s): Bone marrow failure
Abstract: PB1767
Type: Publication Only
Background
Aplastic anaemia is a rare but very serious blood disease, combining a central pancytopenia and bone marrow hypocellularity. Its etiology remains mostly unknown. Treatment is either allogeneic hematopoietic stem cell or on immunosuppressive therapy.
Aims
1- To analyze the epidemiological, clinical and laboratory patients.2. Evaluate the terms and therapeutic results.3- To study the different responses and survival depending on the treatment administered.
Methods
This is a retrospective study conducted over 14 years (January 2000 - December 2013) which included 95 patients with acquired aplastic anemia, diagnosed and treated at the hematology department of the University Hospital Farhat Hached hospital Sousse.
Results
The median age of patients was 32 years. The sex ratio was 1.26. At diagnosis, all patients were symptomatic. An anemic syndrome associated with hemorrhagic syndrome was the main factor of discovery (44.2%). At the initial blood count, pancytopenia was observed in 92.6% of patients. The myelogram showed a poor marrow in 85.2% of patients. A bone marrow biopsy, bone marrow was wealth 0-1 95.8% of patients. Myelosuppression was, moderate in 33 patients (34.7%), severe in 26 patients (27.4%) and severe in 36 patients (37.9%) by the score of Camitta. Fourteen patients underwent a bone marrow allograft. One patient received the anti-lymphocyte serum in combination with ciclosporin. Immunosuppressive treatment with cyclosporin alone was undertaken in 51 of our patients. Forty-two patients received androgen therapy, prescribed alone or in combination with ciclosporin or corticosteroids. At the end of our study: 35 patients (36.8%) were in CR, 6 patients (6.3%) in PR, 14 patients (14.7%) and RM 39 patients (41.1%) in Failure . One patient was lost to follow just after diagnosis. The factors that significantly influenced the response were the severity of myelosuppression, sex, hemoglobin, the rate of white blood cell, the neutrophil rate and allograft. The overall survival rate at 2 years was 47.3% at 5 years and 44.9%. The allograft is the most significant prognostic factor for survival.
Conclusion
Despite progress regarding treatment protocols, changes in the Aplastic anaemia is often fatal. The overall mortality rate in our series is due to the problem of access to specific therapies, namely the allogeneic hematopoietic stem cell and lymphocyte serum.
Session topic: E-poster
Keyword(s): Bone marrow failure
Type: Publication Only
Background
Aplastic anaemia is a rare but very serious blood disease, combining a central pancytopenia and bone marrow hypocellularity. Its etiology remains mostly unknown. Treatment is either allogeneic hematopoietic stem cell or on immunosuppressive therapy.
Aims
1- To analyze the epidemiological, clinical and laboratory patients.2. Evaluate the terms and therapeutic results.3- To study the different responses and survival depending on the treatment administered.
Methods
This is a retrospective study conducted over 14 years (January 2000 - December 2013) which included 95 patients with acquired aplastic anemia, diagnosed and treated at the hematology department of the University Hospital Farhat Hached hospital Sousse.
Results
The median age of patients was 32 years. The sex ratio was 1.26. At diagnosis, all patients were symptomatic. An anemic syndrome associated with hemorrhagic syndrome was the main factor of discovery (44.2%). At the initial blood count, pancytopenia was observed in 92.6% of patients. The myelogram showed a poor marrow in 85.2% of patients. A bone marrow biopsy, bone marrow was wealth 0-1 95.8% of patients. Myelosuppression was, moderate in 33 patients (34.7%), severe in 26 patients (27.4%) and severe in 36 patients (37.9%) by the score of Camitta. Fourteen patients underwent a bone marrow allograft. One patient received the anti-lymphocyte serum in combination with ciclosporin. Immunosuppressive treatment with cyclosporin alone was undertaken in 51 of our patients. Forty-two patients received androgen therapy, prescribed alone or in combination with ciclosporin or corticosteroids. At the end of our study: 35 patients (36.8%) were in CR, 6 patients (6.3%) in PR, 14 patients (14.7%) and RM 39 patients (41.1%) in Failure . One patient was lost to follow just after diagnosis. The factors that significantly influenced the response were the severity of myelosuppression, sex, hemoglobin, the rate of white blood cell, the neutrophil rate and allograft. The overall survival rate at 2 years was 47.3% at 5 years and 44.9%. The allograft is the most significant prognostic factor for survival.
Conclusion
Despite progress regarding treatment protocols, changes in the Aplastic anaemia is often fatal. The overall mortality rate in our series is due to the problem of access to specific therapies, namely the allogeneic hematopoietic stem cell and lymphocyte serum.
Session topic: E-poster
Keyword(s): Bone marrow failure
{{ help_message }}
{{filter}}